Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2). [electronic resource]
Producer: 20200828Description: 613-622 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Docetaxel -- therapeutic use
- Female
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Progression-Free Survival
- Salvage Therapy -- methods
- Treatment Outcome
- Triazoles -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.